Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial-Reference-Cited by-同舟云学术

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Published:2023-01 Issue:1 Volume:88 Page:29-39
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Armstrong April W.,Gooderham Melinda,Warren Richard B.,Papp Kim A.,Strober Bruce,Thaçi Diamant,Morita Akimichi,Szepietowski Jacek C.,Imafuku Shinichi,Colston Elizabeth,Throup John,Kundu Sudeep,Schoenfeld Steve,Linaberry Misti,Banerjee Subhashis,Blauvelt Andrew

Funder

Bristol-Myers Squibb Canada

Manchester Biomedical Research Centre

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Dermatology

Reference20 articles.

1. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain;Burke;Sci Transl Med,2019

2. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors;Nogueira;Drugs,2020

3. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases;Schwartz;Nat Rev Drug Discov,2017